Roche said that its CD20 antibody obinutuzumab (Gazyva/Gazyvaro) has provided significant benefit to patients with indolent non-Hodgkin’s lymphoma paving the way for regulatory filings in the US, European Union and elsewhere. ---Subscribe to MedNous to access this article--- Clinical Research Company News
